Website maintenance may cause short outages or slow response times from November 8 at 10 pm until November 10 at 5 pm.
Overview
The proposed Calgary Radiopharmaceutical Centre (CRC) will be home to Calgary’s first and Alberta’s third cyclotron. This new facility will support the treatment of diseases including cancer, cardiac, and neurological conditions. The Development Permit for the CRC will be submitted in fall 2024 with a target to complete construction within 5 years.
Get informed
For additional details:
Facility safety
Cyclotrons adhere to stringent safety regulations enforced by the Canadian Nuclear Safety Commission (CNSC). The facility incorporates multiple safety layers, including shielding, containment, and operational monitoring.
Safety begins with the facility's design, including concrete walls 6 feet thick. The facility employs a sophisticated radiation monitoring system including detectors, handheld survey meters, and contamination meters, to prevent accidental removal of radioactive material.
A containment system holds radioactive gases until they decay into non-radioactive elements, preventing their release into the atmosphere. For more information about safety regulation visit CNSC.
Alberta Health Services (AHS) is responsible for the public disclosure of any incidents that may occur on site through operation of this facility. To view the notification and disclosure requirements, visit AHS Cyclotron Public Disclosure.
Operation of the facility
The facility will be operated by AHS and utmost care will be undertaken by Foothills Medical Centre Staff to ensure its safe operations.
Construction impacts
Construction will be undertaken with the community in mind. These activities may cause short term impacts to the neighbourhood and Alberta Infrastructure will aim to minimize those impacts where possible.
Sign up for updates
Complete the form below to sign up for project updates.
CRC project survey
To help us improve our materials and the information we share, take 2 minutes to complete our project survey.